The Hospital Care artnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter hospital care partnering deals.
Fresenius is a large pharmaceutical company developing pharmaceutical products and medical devices for critically care and chronically ill patients. ‘Caring for life’ is the motto behind the company’s worldwide success and commitment to patient care.
The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »
The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.
Arbor Pharmaceuticals LLC is allegedly exploring a potential acquisition and merger partner that could bring in more than $1 billion, according to people who are close to the situation.
Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials
AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.
The timing may be right for a takeover of Cubist Pharmaceuticals.
Sciclone Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing products to treat oncology, infectious diseases and urology.
By Steve Poile With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.
Sorry, your search returned no results.
Irish drug giant Shire plc, will pay Boston Children’s Hospital an undisclosed amount under a three-year research pharma partners agreement intended to find new candidates to treat a range of rare pediatric diseases. This pharma partners agreement intends to fulfill the goal of developing novel therapies to treat a number of rare pediatric diseases with more »
In a financing venture, Universal Hospital Services intends to offer up to $425 million in aggregate principal amount of second lien senior secured notes.
Childrens Hospital Boston and Pfizer have launched a new collaborative program aimed at identifying potential drug therapies for Duchenne muscular dystrophy (DMD).
BioAlliance Pharma will co-promote Seroplex® to its core healthcare partners (notably oncologists, radiotherapists and hematologists) as part of a comprehensive approach to patient management in general and cancer therapy in particular, in line with France’s national guidelines for cancer patients.